Related Experiment Videos
Stimulation tests for the bone marrow neutrophil pool in malignancies
P B Hansen1, L M Knudsen, H E Johnsen
1Department of Hematology L, Herlev Hospital, University of Copenhagen, Denmark.
Leukemia & Lymphoma
|January 1, 1995
Summary
A novel 24-hour stimulation test using recombinant human growth factors like rhG-CSF can predict chemotherapy-induced neutropenia. This test helps identify patients who may benefit from prophylactic growth factor administration.
Area of Science:
- Hematology
- Oncology
- Biotechnology
Background:
- Neutrophilia, an increase in neutrophils, can result from various mechanisms including increased release from bone marrow reserves.
- Historically, agents like etiocholanolone and steroids induced neutrophilia, but adverse effects limited their use in predicting chemotherapy tolerance.
- Assessing bone marrow reserve capacity is crucial for determining safe chemotherapy doses and preventing neutropenia.
Observation:
- Recombinant human hematopoietic growth factors, such as granulocyte colony-stimulating factor (rhG-CSF) and granulocyte-macrophage CSF (rhGM-CSF), stimulate myelopoiesis and mobilize mature neutrophils.
- Bone marrow cellularity appears to influence neutrophil mobilization following a single subcutaneous injection of rhG-CSF or rhGM-CSF.
- A pilot study suggested a "24-hour stimulation test" using these growth factors could predict severe neutropenia after cyclic chemotherapy.
Findings:
- The "24-hour stimulation test" demonstrates that bone marrow response to rhG-CSF or rhGM-CSF can predict the degree of neutrophil mobilization.
- This test provides a functional assessment of bone marrow reserve capacity in response to growth factor stimulation.
- Case reports illustrate the concept, showing how the test can anticipate neutropenia severity.
Implications:
- The "24-hour stimulation test" offers a potential strategy to identify patients at risk for severe neutropenia during chemotherapy.
- It may guide prophylactic administration of growth factors to mitigate chemotherapy-induced neutropenia.
- This approach could lead to personalized treatment strategies in oncology, optimizing patient outcomes and safety.